Adaptation and Evaluation of a Symptom-Monitoring Digital Health Intervention for Patients With Relapsed and Refractory Multiple Myeloma: Pilot Mixed-Methods Implementation Study
BackgroundRelapsed and refractory multiple myeloma (RRMM) is a bone marrow cancer that requires systemic treatment, which often results in severe symptom burden. Recent studies have found that electronic patient-reported outcome (ePRO) interventions implemented in the clinic...
Main Authors: | Biran, Noa, Anthony Kouyaté, Robin, Yucel, Emre, McGovern, Gillian E, Schoenthaler, Antoinette M, Durling, Olivia G, Unawane, Rashmi, Schutt, Andrew, Panjabi, Sumeet |
---|---|
Format: | Article |
Language: | English |
Published: |
JMIR Publications
2020-11-01
|
Series: | JMIR Formative Research |
Online Access: | http://formative.jmir.org/2020/11/e18982/ |
Similar Items
-
The value of survival gains from therapeutic innovations for US patients with relapsed/refractory multiple myeloma
by: Joanna P MacEwan, et al.
Published: (2021-07-01) -
Lenalidomide for relapsed or refractory multiple myeloma
by: S. S. Bessmeltsev1, et al.
Published: (2014-07-01) -
Selinexor in relapsed/refractory multiple myeloma
by: Joshua Richter, et al.
Published: (2020-06-01) -
Carfilzomib for relapsed and refractory multiple myeloma
by: Groen K, et al.
Published: (2019-04-01) -
Lenalidomide for relapsed or refractory multiple myeloma
by: S. S. Bessmeltsev1, et al.
Published: (2014-07-01)